



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Genetic stratification to identify risk groups for Alzheimer's disease

Citation for published version:

Marioni, R, Campbell, A, Hagenaars, S, Nagy, R, Amador, C, Hayward, C, Porteous, D, Visscher, PM & Deary, I 2017, 'Genetic stratification to identify risk groups for Alzheimer's disease', *Journal of Alzheimer's Disease*, vol. 57, no. 1, pp. 275-283. <https://doi.org/10.3233/JAD-161070>

Digital Object Identifier (DOI):

[10.3233/JAD-161070](https://doi.org/10.3233/JAD-161070)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Journal of Alzheimer's Disease

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Genetic Stratification to Identify Risk Groups for Alzheimer's Disease

Riccardo E. Marioni^{a,b,c,*}, Archie Campbell^b, Saskia P. Hagenaars^{a,d,e}, Reka Nagy^f,
Carmen Amador^f, Caroline Hayward^f, David J. Porteous^{a,b}, Peter M. Visscher^{a,c} and Ian J. Deary^{a,d}

^aCentre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK

^bMedical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

^cInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia

^dDepartment of Psychology, University of Edinburgh, Edinburgh, UK

^eDivision of Psychiatry, University of Edinburgh, Edinburgh, UK

^fMedical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

Handling Associate Editor: M. Arfan Ikram

Accepted 12 January 2017

Abstract. Stratification by genetic risk factors for Alzheimer's disease (AD) may help identify groups with the greatest disease risk. Biological changes that cause late-onset AD are likely to occur years, if not decades prior to diagnosis. Here, we select a subset of the Generation Scotland: Scottish Family Health Study cohort in a likely preclinical age-range of 60–70 years (subset $n = 3,495$ with cognitive and genetic data). We test for cognitive differences by polygenic risk scores for AD. The polygenic scores are constructed using all available SNPs, excluding those within a 500 kb distance of the *APOE* locus. Additive and multiplicative effects of *APOE* status on these associations are investigated. Small memory decrements were observed in those with high polygenic risk scores for AD (standardized beta -0.04 , $p = 0.020$). These associations were independent of *APOE* status. There was no difference in AD polygenic scores across *APOE* haplotypes ($p = 0.72$). Individuals with high compared to low polygenic risk scores for AD (top and bottom 5% of the distribution) show cognitive decrements, albeit much smaller than for *APOE* $\epsilon 4\epsilon 4$ compared to $\epsilon 3\epsilon 3$ individuals (2.3 versus 3.5 fewer points on the processing speed test, and 1.8 versus 2.8 fewer points on the memory test). Polygenic risk scores for AD may help identify older individuals at greatest risk of cognitive decline and preclinical AD.

Keywords: Alzheimer's disease, apolipoprotein E, cognitive function, genetics, polygenic traits

INTRODUCTION

It is widely acknowledged that the neuropathological hallmarks of Alzheimer's disease (AD) present many years prior to diagnosis [1]. Cognitive

decrements are expected to be observed closer to clinical diagnosis [1]. Targeting individuals who are likely to be in the earliest stages of the disease is therefore a key focus for clinical trials and interventions [2–4].

Age is the biggest risk factor for AD although there are also genetic components to the disease. The apolipoprotein gene, *APOE*, which is involved in lipid transportation, confers the greatest known genetic risk of AD [5, 6]. *APOE* $\epsilon 4\epsilon 4$ homozygotes

*Correspondence to: Riccardo E. Marioni, Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK. Tel.: +44 0 131 651 8528; E-mail: riccardo.marioni@ed.ac.uk.

41 have a 14.9 increased odds of developing dementia
42 compared to those with the $\epsilon 3\epsilon 3$ reference haplotype
43 [7]. The $\epsilon 4$ allele has a frequency in the general pop-
44 ulation of around 15% [8], implying that just over
45 2% of the population are $\epsilon 4\epsilon 4$ homozygotes. Despite
46 the well-replicated association between *APOE* and
47 AD, relatively little is known about its functional role
48 in the disease process [5], although many biological
49 processes including neuroinflammation, neurotoxic-
50 ity, and lipid metabolism among others have been
51 highlighted [6].

52 In addition to *APOE*, several other genes have
53 been implicated in the pathogenesis of AD [9]. As
54 with many other diseases, AD is a polygenic trait
55 whereby many genetic polymorphisms of small effect
56 are likely to contribute to the disease process [9]. One
57 method that incorporates many of these variants into
58 a single measure is polygenic risk scoring [10]. This
59 method uses existing results from genome-wide asso-
60 ciation studies (GWAS) to provide weights specific
61 to each genetic polymorphism, which can then be
62 applied to independent cohorts. Thus, each individual
63 in an independent cohort can be assigned a genetic
64 risk score that is based on potentially thousands of
65 genetic variants that individually explain some frac-
66 tion of the risk of AD. For example, polygenic scores
67 for AD predict around 2% of the variance of AD in
68 an independent cohort [11]. AD polygenic risk scores
69 were also shown to discriminate best between cases
70 and controls between the ages of 60 and 70 years [11].

71 Given the low frequency of the $\epsilon 4\epsilon 4$ haplo-
72 type, large sample population-based cohorts are
73 required to study its effects with precision. A pre-
74 vious study utilizing one such cohort, Generation
75 Scotland ($n = 18,337$), investigated cognitive ability
76 by *APOE* status [12]. It found evidence for poorer
77 memory and processing speed in $\epsilon 4\epsilon 4$ homozygotes
78 (compared to $\epsilon 3\epsilon 3$ homozygotes) in a sub-sample of
79 participants aged over 60 years. These age-stratified
80 findings coincide with the theoretical predictions of
81 Sperling et al. [1]. Furthermore, given the prediction
82 models of AD development, it is plausible that cogni-
83 tive decrements predictive of AD will be most notable
84 in populations between the ages of 60 and 70, i.e.,
85 the decade prior to an exponential increase in AD
86 diagnosis.

87 The primary aim of this study is to test if there are
88 cognitive decrements in those with a high polygenic
89 risk of AD and to see how these effects compare with
90 *APOE* $\epsilon 4\epsilon 4$ status. The analysis will focus on a sub-
91 group from the Generation Scotland cohort in the age
range of 60 to 70 years.

MATERIALS AND METHODS

Generation Scotland: Scottish Family Health Study

Data came from Generation Scotland: Scottish
Family Health Study (hereafter referred to as Gen-
eration Scotland), a large population-based cohort
sampled from five regional centers across Scot-
land [13, 14]. Initial recruitment focused on 7,953
individuals aged between 35 and 65 years, who
were registered with a participating General Prac-
tice surgery; around 96% of the UK population is
registered with a general medical practitioner. Rel-
atives of these probands were then recruited. There
were up to three generations of $\sim 7,000$ participat-
ing families in the study, recruited between 2006
and 2011, yielding a cohort of over 24,000 subjects.
There was no intended recruitment enrichment for
any disease or health condition. Details on cognitive,
anthropometric, and health measures were recorded.
A full description of the cohort and the data col-
lected have been reported elsewhere [13, 14] and at
<http://www.generationscotland.org>.

Cognitive data

As previously described, four domains of cognitive
function were assessed by single tests in nearly all
Generation Scotland participants ($n = 21,524$): pro-
cessing speed (Wechsler Digit Symbol Substitution
Test [15]), verbal declarative memory (Wechsler Log-
ical Memory Test; sum of immediate and delayed
recall of one paragraph [16]), verbal fluency (the
phonemic Verbal Fluency Test; using the letters C,
F, and L, each for one minute [17]), and vocabulary
(the Mill Hill Vocabulary Scale; junior and senior
synonyms combined [18]). As a previous Genera-
tion Scotland study showed evidence for age-related
cognitive decrements in processing speed and ver-
bal declarative memory but not verbal fluency or
vocabulary [12], we focused here on the former two
outcomes only.

Genetic data

Genome wide genotyping and *APOE* haplotyping
details have been described previously [12]. Briefly,
Generation Scotland participants were genotyped
with either the HumanOmniExpressExome8v1-2_A
or HumanOmniExpressExome-8v1_A. Quality con-
trol was carried out in PLINK version 1.9b2c [19, 20].




Fig. 1. Flowchart documenting the selection process of the Generation Scotland analysis cohorts.

SNPs were removed if they had a missingness rate $>2\%$ or a Hardy-Weinberg Equilibrium test $p < 10^{-6}$. Duplicate samples were removed. Individuals were removed based on gender mismatch and missingness ($>2\%$ of genotypes missing). The subsequent data were combined with the 1,092 individuals of the 1000 Genomes population [21] prior to principal components being calculated in GCTA [22]. Outliers, defined by being more than six standard deviations away from the mean of the first two principal components, were removed [23]. This left a sample of 20,032 participants.

APOE haplotype status depends on the genotypes of two single nucleotide polymorphisms (SNPs), rs429358 and rs7412 that can form three possible haplotypes: $\epsilon 2$, $\epsilon 3$, and $\epsilon 4$ [24]). Array genotyping of these SNPs is technically difficult and, as a result, they are not available on the majority of commercial arrays. SNP genotypes were thus obtained using Taqman technology at the Wellcome Trust Clinical Research Facility Genetics Core, Edinburgh. Blood samples from Generation Scotland participants were collected, processed, and stored using standard operating procedures and managed through a laboratory information management system at the Wellcome Trust Clinical Research Facility Genetics Core, Edinburgh [25]. *APOE* genotyping data were available on 21,039 individuals.

Analysis cohort

After merging the *APOE*, GWAS, and cognitive data, and after excluding individuals with

self-reported AD (or a missing value) and restricting the cohort to individuals aged between 60 and 70 years, inclusive, the analysis population contained 3,495 participants. A flowchart documenting the selection process is provided in Fig. 1.

Polygenic risk scores

Polygenic risk scores for AD were calculated using the PRSice software program with LD clumping parameters set to $R^2 > 0.25$ over 250 kb sliding windows [26]. The discovery GWAS from which the SNP weights were extracted was the Stage I AD GWAS analysis by Lambert et al. [27]. The Generation Scotland polygenic scores were generated using all possible SNPs ($p < 1$) from the discovery GWAS [27] but excluding those within a 500 kb window of *APOE*. The $p < 1$ selection threshold was based on previous polygenic score models for AD, verbal-numerical reasoning (cognitive ability), and educational attainment [11, 28]. In these studies, while $p < 1$ was not the optimal threshold for AD and verbal-numerical reasoning ($p < 0.5$ and $p < 0.05$, respectively), there were negligible differences with the results for the $p < 1$ threshold. A total of 539,368 genotyped Generation Scotland SNPs (with MAF $< 5\%$) were used to construct the score using weights from the Stage I analysis of Lambert et al. [27]. The Lambert et al. study was a meta-analysis GWAS of the 1000 Genomes imputed SNPs ($n_{\text{SNPs}} > 7,000,000$). After excluding 2,581 SNPs within a 500 kb region of *APOE*, we mapped the remaining SNPs to the overlapping genotyped variants in Generation Scotland.

A summary of the methods and acknowledgements from the discovery GWAS [27] are presented in the Supplementary Material.

Ethics

All components of Generation Scotland received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). Generation Scotland has also been granted Research Tissue Bank status by the Tayside Committee on Medical Research Ethics (REC Reference Number: 15/0040/ES), providing generic ethical approval for a wide range of uses within medical research.

Statistical analyses

Linear mixed modelling was used to test for differences in cognitive ability by AD polygenic risk scores and *APOE* status. A mixed modelling framework is necessary to account for potential relatedness between participants; familial relationships were fitted using a pedigree-based kinship matrix. The polygenic score was entered as either a continuous variable or as ventiles (5% groupings) of risk. A fully adjusted model added self-reported educational attainment, hypertension, stroke, diabetes, heart disease, and depression, along with a measure of social deprivation (Scottish Index of Multiple Deprivation) [12]. A sample size of 3,495 is sufficient to detect an effect size with an R^2 of 0.18% for a type-I error of $\alpha = 0.05$ at 80% power using a one-sided test. *APOE* was entered as a factor with $\epsilon 3$ homozygotes as the reference category for all other haplotype combinations.

All analyses were conducted in R, using the 'pwr', 'kinship2', and 'coxme' packages [29–32].

RESULTS

Description of the polygenic risk score cohort ($n = 3,625$, age-range 60–70 years)

A demographic summary of the target population aged between 60 and 70 years and with AD polygenic risk scores is presented in Table 1. The median age of the cohort was 63 (IQR 61–65) and 57% were female. The mean BMI of the cohort was 27.5 kg/m^2 (SD 5.0). The median educational attainment was 12–13 years (measured categorically). The self-reported health questionnaire identified 27% of participants with

Table 1

Summary of the Generation Scotland AD polygenic risk cohort

Variable	Polygenic risk cohort		
	n	mean	sd
Age (years – median, IQR)	3,495	63	61–65
Digit Symbol Test	3,495	62.5	14.4
Logical Memory	3,495	29.5	8.0
SIMD (rank, median, IQR)*	3,318	4566	2924–5542
Educational attainment [†]	3,365	4	3–5
		n	%
Sex (Female)		1,998	57.2
Self-report hypertension (yes)		929	26.6
Self-report stroke (yes)		79	2.3
Self-report diabetes (yes)		194	5.6
Self-report heart disease (yes)		285	8.2
Self-report depression (yes)		298	8.5
<i>APOE</i>			
$\epsilon 2\epsilon 2$		19	0.5
$\epsilon 2\epsilon 3$		437	12.5
$\epsilon 2\epsilon 4$		86	2.5
$\epsilon 3\epsilon 3$		2,081	59.5
$\epsilon 3\epsilon 4$		782	22.4
$\epsilon 4\epsilon 4$		90	2.6

*Scottish Index of Multiple Deprivation. [†]Education was measured as an ordinal variable, so median and quartiles are reported. 0: 0 years, 1: 1–4 years, 2: 5–9 years, 3: 10–11 years, 4: 12–13 years, 5: 14–15 years, 6: 16–17 years, 7: 18–19 years, 8: 20–21 years, 9: 22–23 years, 10: ≥ 24 years.

self-reported hypertension, 9% with depression, 6% with diabetes, 2% with stroke, and 8% with heart disease.

Cognitive differences by AD polygenic score with and without adjustment for *APOE* status ($n = 3,625$, age-range 60–70 years)

There was a statistically significant association between the polygenic score and memory (Table 2): effect size of -0.31 points per SD of the polygenic score, SE 0.14, $p = 0.020$. A similar effect size was observed for processing speed although it was not significantly different from the null (effect size -0.27 , SE 0.24, $p = 0.25$). There was no difference in polygenic score by *APOE* genotype (age- and sex-adjusted ANOVA $p = 0.72$). Moreover, the effect size for the polygenic score in the memory model remained significant and was not attenuated after adjusting for *APOE* haplotype (effect size -0.30 points, SE = 0.14, $p = 0.025$); there was also no evidence for an *APOE* x polygenic score interaction (likelihood ratio test $P = 0.40$). Similarly, there was no evidence of an *APOE* x polygenic score interaction for the processing speed model (likelihood ratio test $p = 0.86$). In the fully adjusted models, which controlled for self-reported diabetes, stroke, heart disease, diabetes, and

Table 2
Comparison of cognitive outcomes by genetic risk for AD and *APOE* status. All models adjust for age, sex, and pedigree-based relatedness

Variable	beta	SE	<i>p</i>	FDR Adjusted <i>p</i> *
Effect per SD of PGRS				
Digit Symbol Test	-0.28	0.24	0.25	0.25
Logical Memory	-0.31	0.14	0.020	0.04
Top versus Bottom 5% of PGRS				
Digit Symbol Test	-2.32	1.54	0.13	0.15
Logical Memory	-1.84	0.83	0.028	0.04
<i>APOE</i> ε4ε4 versus ε3ε3				
Digit Symbol Test	-3.51	1.53	0.022	0.04
Logical Memory	-2.78	0.86	1.2×10^{-3}	0.007

PGRS, Polygenic risk score; SD, standard deviation; SE, standard error. *False discovery rate adjusted *p*-values after applying a Benjamini-Hochberg correction to the six empirical *p*-values.

depression, along with educational attainment and a social deprivation index, there was a slight increase in the effect size of the polygenic score on both the memory and processing speed measures: effect sizes of -0.34, SE 0.14, *p* = 0.014 and -0.31, SE 0.24, *p* = 0.20, respectively.

Cognitive differences in the top versus bottom 5% of the polygenic score distribution (age-range 60–70 years)

A significant association was observed in the age- and sex-adjusted analyses that compared the top and bottom ventile (5%) of the polygenic distribution for memory differences. Those in the top (highest AD risk) ventile scored a mean of 1.8 points (SE 0.8, *p* = 0.028) lower than those in the bottom ventile on the memory test; for processing speed, those in the top ventile scored a mean of 2.3 points (SE 1.5, *p* = 0.13) lower than the bottom ventile.

Cognitive differences by *APOE* status (*n* = 3,625, age-range 60–70 years)

In a regression of cognitive ability on age, sex, and *APOE*, ε4ε4 homozygotes scored a mean of 2.8 and 3.5 points lower on memory and processing speed (*p* = 0.001 and *p* = 0.022, respectively) compared to ε3ε3 homozygotes.

Sensitivity and secondary analyses

While a kinship matrix was included to model relatedness between participants, a sensitivity analysis on only unrelated individuals was performed. A genetic relationship matrix was created in GCTA and unrelated individuals (relationship coefficient < 0.025) were retained (*n* = 2,677). In this sub-group,

we observed results consistent with the primary analysis (Supplementary Table 1).

A second sensitivity analysis was run after excluding those with fewer than 5 years of education (*n* = 12) or a missing value for education (*n* = 130). These results were consistent with the primary analysis (Supplementary Table 2).

To determine if cognitive decrements by AD polygenic scores were present at younger ages, we selected an analysis sub-cohort in the age range of 45 to 60 years (*n* = 6,853). We observed generally smaller effect sizes to the 60 to 70 sub-group that were all non-significant (Supplementary Table 3). Similarly, we observed null associations between the polygenic score and cognitive decrements in a sub-group of participants aged over 70 years (Supplementary Table 4).

DISCUSSION

In a group of over 3,000 individuals aged between 60 and 70 years, polygenic risk scores for AD were associated with decrements for memory but not processing speed. This was the case when considering polygenic risk on a continuum and also when comparing the extremes (top and bottom 5%) of the distribution. Furthermore, a higher AD polygenic risk score was associated with an increased odds of family history of AD in an extended sample of 6,724 unrelated participants of all ages. A significant association was only present when comparing the extremes of the distribution rather than a continuous polygenic score. This increased risk was independent of *APOE* status. Relative to ε3ε3 homozygotes (59.5% of the study population), *APOE* ε4ε4 homozygotes (2.6% of the study population) carried a lower risk of familial AD than those in the top 5% of the AD polygenic

burden compared to those in the bottom 5%. Furthermore, although a relatively large point estimate was observed in the expected direction, the $\epsilon 4\epsilon 4$ association was not significantly associated with family history of AD, unlike $\epsilon 4$ presence (versus absence). This is likely to be due to a lack of statistical power.

The main limitation of the current study is the sample size. The *post hoc* power calculations showed that the total number of participants in the 60–70 age range was only just sufficient to detect relatively small memory decrements by AD polygenic score status. The relatively modest association *p*-values for the primary analyses (Table 2) reflect this lack of power. The associations remained significant after a FDR correction; only the *APOE* association with Logical Memory would remain significant after a Bonferroni correction ($p < 0.05/6$).

Another possible limitation is the construction of the AD polygenic risk predictor. As the number of cases and controls increases in the discovery GWAS [27], the precision and reliability of the SNP regression weights will improve. The cross-sectional design of the Generation Scotland analysis may also be a limitation, as might the lack of information on subjective memory complaints. One recent study showed that a high genetic score for AD (based on 22 top SNP hits from a GWAS study) was associated with steeper decline in memory, although the magnitude of the effect was reduced when the *APOE* locus was removed from the score [33].

With sufficiently large sample sizes, it is likely that cognitive differences in processing speed will be present in the general population for those with high versus low polygenic risk of AD. Larger discovery GWAS studies will also help to identify the optimal number of SNPs (all SNPs in a truly polygenic architecture versus a smaller number of possibly more biologically informative SNPs) for a polygenic predictor. The genetic contribution to AD has been shown to overlap with the genetics of education, intelligence, and income but not other health, disease, or psychiatric outcomes [28, 34, 35]. Intuitively, we would therefore expect to see phenotypic differences across all ranges of the polygenic scores and more acutely with the extremes of the distribution.

The most comprehensive study to have examined the association between polygenic scores for AD with cognitive function [27] used a predictor based on the Lambert et al. discovery GWAS [11]. The independent target dataset in that study was the UK Biobank study. Small but significant associations, not explaining more than 0.05% of the variance in three

cognitive traits and 0.07% of the variance in educational attainment [28].

In conclusion, there is potential clinical utility for the stratification of mid-to-late-life population-based cohorts into high and low risk groups (based on *APOE* status and global polygenic risk) to better understand the pathophysiology of AD. However, large sample sizes for both the GWASs used to build the polygenic scores and to select at risk sub-groups of the population are likely to be necessary. By contrast, smaller sample sizes are likely to be required when stratifying by *APOE* $\epsilon 4\epsilon 4$ status, as effect sizes are far greater in magnitude. Nonetheless, with increasingly powerful polygenic predictors—as a result of bigger baseline GWAS studies—it seems likely that the extremes of the distribution will provide high risk groups equivalent to those with two $\epsilon 4$ alleles. However, the extremes of the polygenic score distribution will be of additional value as, by definition of their construction, they will tap into genome wide risk and multiple pathways that lead to AD. Longitudinal collection of cognitive test data in addition to biomarker panels and ‘omics data, such as methylomics, which have been linked to AD pathology [36] may help illuminate biological signatures for AD, and improve long-term prediction of the disease.

ACKNOWLEDGMENTS

This work was supported by multiple sources. Generation Scotland received core funding from the Chief Scientist Office of the Scottish Government Health Directorates CZD/16/6 and the Scottish Funding Council HR03006. We are grateful to all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was funded by the UK Medical Research Council (MRC). The Quantitative Trait Locus team at the Human Genetics Unit are funded by the MRC. REM, SPH, DJP, PMV, and IJD undertook the work within The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology (MR/K026992/1), part of the cross council Lifelong Health and

Wellbeing Initiative. Funding from the BBSRC, and MRC is gratefully acknowledged. We thank Professor Julie Williams for providing comments on an early draft of the manuscript.

Authors' disclosures available online (<http://j-alz.com/manuscript-disclosures/16-1070r2>).

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: <http://dx.doi.org/10.3233/JAD-161070>.

REFERENCES

- [1] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7, 280-292.
- [2] Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S (2016) Development of interventions for the secondary prevention of Alzheimer's dementia: The European Prevention of Alzheimer's Dementia (EPAD) project. *Lancet Psychiatry* 3, 179-186.
- [3] Ritchie CW, Ritchie K (2012) The PREVENT study: A prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease. *BMJ Open* 2, pii: e001893.
- [4] Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jönsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H (2016) Defeating Alzheimer's disease and other dementias: A priority for European science and society. *Lancet Neurol* 15, 455-532.
- [5] Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. *Nat Rev Neurol* 9, 106-118.
- [6] Yu JT, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer's disease: An update. *Annu Rev Neurosci* 37, 79-100.
- [7] Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmechel KE (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat Genet* 7, 180-184.
- [8] Eisenberg DT, Kuzawa CW, Hayes MG (2010) Worldwide allele frequencies of the human apolipoprotein E gene: Climate, local adaptations, and evolutionary history. *Am J Phys Anthropol* 143, 100-111.
- [9] Escott-Price V, Bellenguez C, Wang LS, Choi SH, Harold D, Jones L, Holmans P, Gerrish A, Vedernikov A, Richards A, DeStefano AL, Lambert JC, Ibrahim-Verbaas CA, Naj AC, Sims R, Jun G, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Denning N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Schmidt H, Kunkle B, Dunstan ML, Vronskaya M, Johnson AD, Ruiz A, Bioreau MT, Reitz C, Pasquier F, Hollingworth P, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Hernández I, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, George-Hyslop PS, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tzolaki M, Bossú P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Garcia FS, Fox NC, Hardy J, Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Scarpini E, Bonuccelli U, Mancuso M, Siciliano G, Moebus S, Mecocci P, Zompo MD, Maier W, Hampel H, Pilotto A, Frank-García A, Panza F, Solfrizzi V, Caffarra P, Nacmias B, Perry W, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razuin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nöthen MM, Graff C, Psaty BM, Haines JL, Lathrop M, Pericak-Vance MA, Launer LJ, Van Broeckhoven C, Farrer LA, van Duijn CM, Ramirez A, Seshadri S, Schellenberg GD, Amouyel P, Williams J, Olson J, Kronmal R, Arnold AM, Robbins J, Carlson M, Burke G, Kuller LH, Tracy R, Gottdiener J, Prineas R, Becker JT, Enright P, Klein R, O'Leary DH (2014) Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. *PLoS One* 9, e94661.
- [10] Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 460, 748-752.
- [11] Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, Badarinarayan N, Morgan K, Passmore P, Holmes C, Powell J, Brayne C, Gill M, Mead S, Goate A, Cruchaga C, Lambert JC, van Duijn C, Maier W, Ramirez A, Holmans P, Jones L, Hardy J, Seshadri S, Schellenberg GD, Amouyel P, Williams J, Abraham R, Hollingworth P, Gerrish A, Chapman J, Russo G, Hamsheer M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan A, Taylor S, Lovestone S, Proitsi P, Lupton MK, Rubinsztein DC, Lawlor B, Lynch A, Brown K, Craig D, McGuinness B, Todd S, Johnston J, Mann D, Smith A, Love S, Kehoe PG, Fox N, Rossor M, Collinge J, Jessen F, Heun R, Schürmann B, Becker T, Herold C, Lacour A, Drichel D, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Kauwe JS, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Muhleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG,

- 560 ODonovan M, Owen MJ (2015) Common polygenic varia-
561 tion enhances risk prediction for Alzheimer's disease. *Brain*
562 **138**(Pt12), 3673-3684.
- [12] Marioni RE, Campbell A, Scotland G, Hayward C, Porteous
563 DJ, Deary IJ (2016) Differential effects of the APOE $\epsilon 4$
564 allele on different domains of cognitive ability across the
565 life-course. *Eur J Hum Genet* **24**, 919-923.
- [13] Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jack-
566 son C, Kerr SM, Deary IJ, Macintyre DJ, Campbell H,
567 McGilchrist M, Hocking LJ, Wisely L, Ford I, Lindsay RS,
568 Morton R, Palmer CN, Dominiczak AF, Porteous DJ, Mor-
569 ris AD (2013) Cohort Profile: Generation Scotland: Scottish
570 Family Health Study (GS:SFHS). The study, its participants
571 and their potential for genetic research on health and illness.
572 *Int J Epidemiol* **42**, 689-700.
- [14] Smith BH, Campbell H, Blackwood D, Connell J, Connor
573 M, Deary IJ, Dominiczak AF, Fitzpatrick B, Ford I, Jackson
574 C, Haddow G, Kerr S, Lindsay R, McGilchrist M, Morton
575 R, Murray G, Palmer CN, Pell JP, Ralston SH, St Clair D,
576 Sullivan F, Watt G, Wolf R, Wright A, Porteous D, Mor-
577 ris AD (2006) Generation Scotland: The Scottish Family
578 Health Study; a new resource for researching genes and
579 heritability. *BMC Med Genet* **7**, 74.
- [15] Wechsler D (1998) WAIS-III UK Wechsler Adult Intelli-
580 gence Scale, Psychological Corporation, London, UK.
- [16] Wechsler D (1998) WMS-III UK, Wechsler Memory Scale-
581 Revised, Psychological Corporation, London, UK.
- [17] Lezak MD (1995) Neuropsychological Assessment, 3rd edition.
582 Oxford University Press, Oxford, UK.
- [18] Raven JC, Court JH, Raven J (1977) Manual for Raven's
583 Progressive Matrices and Vocabulary Scales. HK Lewis,
584 London, UK.
- [19] Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM,
585 Lee JJ (2015) Second-generation PLINK: Rising to the chal-
586 lenge of larger and richer datasets. *Gigascience* **4**, 7.
- [20] Purcell S, Chang CC (2015) PLINK 1.9 package. URL:
587 <https://www.coggenomics.org/plink2>
- [21] The 1000 Genomes Project, Consortium (2010) A map of
588 human genome variation from population-scale sequencing.
589 *Nature* **467**, 1061-1073.
- [22] Yang J, Lee SH, Goddard ME, Visscher PM (2011) GCTA:
590 A tool for genome-wide complex trait analysis. *Am J Hum*
591 *Genet* **88**, 76-82.
- [23] Amador C, Huffman J, Trochet H, Campbell A, Porteous
592 D, Wilson JF, Hastie N, Vitart V, Hayward C, Navarro P,
593 Haley CS (2015) Recent genomic heritage in Scotland. *BMC*
594 *Genomics* **16**, 437.
- [24] Wenhham PR, Price WH, Blandell G (1991) Apolipoprotein
595 E genotyping by one-stage PCR. *Lancet* **337**, 1158-1159.
- [25] Kerr SM, Campbell A, Murphy L, Hayward C, Jackson
596 C, Wain LV, Tobin MD, Dominiczak A, Morris A, Smith
597 BH, Porteous DJ (2013) Pedigree and genotyping quality
598 analyses of over 10,000 DNA samples from the Generation
599 Scotland: Scottish Family Health Study. *BMC Med Genet*
600 **14**, 38.
- [26] Euesden J, Lewis CM, O'Reilly PF (2015) PRSice: Poly-
601 genic Risk Score software. *Bioinformatics* **31**, 1466-1468.
- [27] Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims
602 R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW,
603 Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N,
604 Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D,
605 Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H,
606 Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH,
607 Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr
608 C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA,
609 Evans D, Lovestone S, Letenneur L, Morón FJ, Rubins-
610 stein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet
611 N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller
612 L, Barberger-Gateau P, McGuinness B, Larson EB, Green R,
613 Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva
614 E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A,
615 Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossú P, Spalletta
616 G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC,
617 Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C,
618 Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci
619 P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido
620 M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M,
621 Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM,
622 Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O,
623 Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin
624 C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV,
625 Combaros O, O'Donovan MC, Cantwell LB, Soininen H,
626 Blacker D, Mead S, Mosley TH, Bennett DA, Harris TB,
627 Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine
628 TJ, Bettens K, Rotter JJ, Brice A, Morgan K, Foroud TM,
629 Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie
630 K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider
631 M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu
632 D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman
633 A, Nöthen MM, Graff C, Psaty BM, Jones L, Haines JL,
634 Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ,
635 Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina
636 V, Seshadri S, Williams J, Schellenberg GD, Amouyel P,
637 Alperovitch A, Boland A, Delépoine M, Dubois B, Duron E,
638 Epelbaum J, Van Cauwenbergh C, Engelborghs S, Vanden-
639 berghe R, De Deyn PP, Ferri R, Romano C, Caltagirone C,
640 Orfei MD, Ciarabella A, Scarpini E, Fenoglio C, Siciliano
641 G, Bonuccelli U, Bagnoli S, Bracco L, Bessi V, Cecchetti
642 R, Bastgiani P, Squassina A, Seripa D, Frank-García A,
643 Sastre I, Blesa R, Alcolea D, Suárez-Clavet M, Sánchez-
644 Juan P, Muñoz Fernandez C, Aladro Benito Y, Thonberg
645 H, Forshell C, Lilus L, Kinhult-Ståhlbom A, Giedraitis V,
646 Kilander L, Brundin RM, Conarci L, Helisalmi S, Koivisto
647 AM, Haapasalo A, Solfrizzi V, Frisardi V, Ott J, Carney RM,
648 Mash DC, Albert MS, Albin RL, Apostolova LG, Arnold
649 SE, Barmada MM, Barnes LL, Beach TG, Bigio EH, Bird
650 TD, Bovee BF, Bowen JD, Boxer A, Burk JR, Cairns NJ, Cao
651 C, Carlson CS, Carroll SL, Chibnik LB, Chui HC, Clark DG,
652 Corneveaux J, Cribbs DG, DeCarli C, DeKosky ST, Demirci
653 FY, Dick M, Dickson DW, Duara R, Ertekin-Taner N, Fallon
654 KB, Farlow MR, Ferris S, Frosch MP, Galasko GR, Gan-
655 guli M, Gearing M, Geschwind DH, Ghetti B, Gilman S,
656 Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E,
657 Honig LS, Hulette CM, Hyman BT, Jarvik GP, Jicha GA,
658 Jin LW, Karydas A, Kauwe JS, Kaye JA, Kim R, Koo EH,
659 Kowall NW, Kramer JH, Kramer P, LaFerla FM, Lah JJ,
660 Levernez JB, Levey AI, Li G, Lieberman AP, Lyketsos CG,
661 Mack WJ, Marson DC, Martiniuk F, Masliah E, McCormick
662 WC, McCurry SM, McDavid AN, McKee AC, Mesulam M,
663 Miller BL, Miller CA, Miller JW, Morris JC, Murrell JR,
664 Olichney JM, Pankratz VS, Parasi JE, Peskind E, Peterson
665 RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind
666 M, Raiman EM, Reisberg B, Ringman JM, Roberson ED,
667 Rosen HJ, Rosenberg RN, Sano M, Saykin AJ, Schnei-
668 der JA, Schneider LS, Seely WW, Smith AG, Sonnen JA,
669 Spina S, Stern RN, Tanzi RE, Trojanowski JQ, Troncoso JC,
670 Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP,
671 Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL,
672 Yu CE, Barber R, Au R, Wolf PA, Beiser A, Dobbins S, Yang
673 Q, Weinstein G, Johnson AD, Wang J, Uitterlinden AG,

- 690 Rivadeneira F, Koudstgaal PJ, Longstreth WT, Becker JT, 722
691 Kuller LH, Lumley T, Rice K, Garcia M, Aspelund T, Mark- 723
692 steiner JJ, Dal-Bianco P, Töglhofer AM, Freudenberger P, 724
693 Ransmayr G, Benke T, Toeglhofer AM, Bressler J, Breteler 725
694 MM, Fornage M, Hernández I, Rosende Roca M, Ana 726
695 Mauleón M, Alegrat M, Ramírez-Lorca R, González-Perez 727
696 A, Chapman J, Stretton A, Morgan A, Kehoe PG, Medway 728
697 C, Lord J, Turton J, Hooper NM, Vardy E, Warren JD, Schott 729
698 JM, Uphill J, Ryan N, Rossor M, Ben-Shlomo Y, Makrina 730
699 D, Gkatzima O, Lupton M, Koutroumani M, Avramidou D, 731
700 Germanou A, Jessen F, Riedel-Heller S, Dichgans M, Heun 732
701 R, Kölsch H, Schürmann B, Herold C, Lacour A, Drichel D, 733
702 Hoffman P, Kornhuber J, Gu W, Feulner T, van den Buss- 734
703 che H, Lawlor B, Lynch A, Mann D, Smith AD, Warden 735
704 D, Wilcock G, Heuser I, Wiltgang J, Frölich L, Hüll M, 736
705 Mayo K, Livingston G, Bass NJ, Gurling H, McQuillen A, 737
706 Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Single- 738
707 ton AB, Guerreiro R, Jöckel KH, Klopp N, Wichmann HE, 739
708 Dickson DW, Graff-Radford NR, Ma L, Bisceglia G, Fisher 740
709 E, Warner N, Pickering-Brown S (2013) Meta-analysis of 741
710 74,046 individuals identifies 11 new susceptibility loci for 742
711 Alzheimer's disease. *Nat Genet* **45**, 1452-1458. 743
- [28] Hagenaars SP, Harris SE, Davies G, Hill WD, Liewald DC, 744
712 Ritchie SJ, Marioni RE, Fawns-Ritchie C, Cullen B, Malik 745
713 R, Worrall BB, Sudlow CL, Wardlaw JM, Gallacher J, Pell J, 746
714 McIntosh AM, Smith DJ, Gale CR, Deary IJ (2016) Shared 747
715 genetic aetiology between cognitive functions and phys- 748
716 ical and mental health in UK Biobank (N=112 151) and 24 749
717 GWAS consortia. *Mol Psychiatry* **21**, 1624-1632. 750
- [29] Champely S (2015) pwr: Basic Functions for Power Anal- 751
720 ysis. R package version 1.1-3. <https://CRAN.R-project.org/package=pwr>
- [30] R Core Team (2013) R: A Language and Environment for 722
723 Statistical Computing. 724
- [31] Therneau TM (2015) coxme: Mixed Effects Cox Mod- 725
726 els. R package version 2.2-5. <https://CRAN.R-project.org/package=coxme> 727
- [32] Therneau TM, Sinnwell J (2015) kinship2: Pedigree. Func- 728
729 tions. R package version 1.6.4. <https://CRAN.R-project.org/package=kinship2> 730
- [33] Marden JR, Mayeda ER, Walter S, Vivot A, Tchétgen 731
732 Tchétgen EJ, Kawachi I, Glymour MM (2016) Using an 733
734 Alzheimer disease polygenic risk score to predict mem- 735
736 ory decline in black and white Americans over 14 years 737
738 of follow-up. *Alzheimer Dis Assoc Disord* **30**, 195-202. 739
- [34] Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day 740
741 FR, Loh PR, Duncan L, Perry JR, Patterson N, Robinson EB, 742
743 Daly MJ, Price AL, Neale BM (2015) An atlas of genetic 744
745 correlations across human diseases and traits. *Nat Genet* **47**, 746
747 1236-1241. 748
- [35] Hill WD, Hagenaars SP, Marioni RE, Harris SE, Liewald 749
750 DC, Davies G, Okbay A, McIntosh AM, Gale CR, Deary IJ 751
752 (2016) Molecular genetic contributions to social deprivation 753
754 and household income in UK biobank. *Curr Biol* **26**, 3083- 755
756 3089. 757
- [36] Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava 758
759 G, Volta M, Troakes C, Al-Sarraj S, Burrage J, Macdon- 760
761 ald R, Condliffe D, Harries LW, Katsel P, Haroutunian V, 762
763 Kaminsky Z, Joachim C, Powell J, Lovestone S, Bennett 764
765 DA, Schalkwyk LC, Mill J (2014) Methylomic profiling 766
767 implicates cortical deregulation of ANK1 in Alzheimer's 768
769 disease. *Nat Neurosci* **17**, 1164-1170. 769
770
771